Bristol Steps Back From Diversity Pledge in Bow to Trump.

TRUMP, Donald, 1946-; EMPLOYEE affinity groups; GOING public (Securities); LGBTQ+ employees; DIVERSITY & inclusion policies; VACCINE development

The article discusses how Bristol Myers Squibb Co. has scaled back its diversity, equity, and inclusion efforts in response to pressure from lawsuits and activist movements, including President Donald Trump's executive orders. Other pharmaceutical companies, such as Biogen Inc. and Alnylam Pharmaceuticals Inc., have also made similar changes to their annual reports, removing references to diversity initiatives. The trend of companies retracting DEI commitments is attributed to government actions and potential implications on government health programs that these companies rely on for revenue. [Extracted from the article]

Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)